Released May 15, 2019, after the close
10-Q filed May 15, 2019, 45 days after period end · 0001390478-19-000030
Q1 2019 · 10-Q
Revenue—
Net Income-$4.54M-$4.54M N/M vs Q1 2018N/M vs Q4 2018
EPS Diluted-$11.12-$11.12 N/M vs Q1 2018no prior Q4 2018 on file
Operating Cash Flow-$4,991,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2019 | Q1 2018 | Q1 2017 | Q1 2016 |
|---|---|---|---|---|
| Net Income | -$4.54M | -$8.00M | -$4.60M | -$16.49M |
| EPS Diluted | -$11.12 | -$1.67 | -$3.63 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR